---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-071702"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:10:30.128430+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Catalyst reports record FY2025 revenue $589M (+20% YoY); FY2026 guidance $615-645M

## Summary
- Full year 2025 total revenues $589.0M, up 19.8% YoY; GAAP diluted EPS $1.68 vs $1.31.
- Q4 2025 total revenues $152.6M; FIRDAPSE revenue grew 18.3% in Q4; AGAMREE grew 67.5%.
- FY2026 revenue guidance $615M-$645M; promoted product revenue expected to grow 20%+.
- Non-GAAP net income $346.2M for FY2025 vs $276.3M, up 25.3%.
- Cash and equivalents $709.2M as of Dec 31, 2025, up 37% YoY.

## SEC filing metadata
- accession: 0001193125-26-071702
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312526071702/0001193125-26-071702-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312526071702/d108222d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-071702
- JSON: https://secwatch.observer/filing/0001193125-26-071702.json
- Plain text: https://secwatch.observer/filing/0001193125-26-071702.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.